GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Morepen Laboratories Ltd (NSE:MOREPENLAB) » Definitions » Debt-to-EBITDA

Morepen Laboratories (NSE:MOREPENLAB) Debt-to-EBITDA : 0.00 (As of Dec. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Morepen Laboratories Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Morepen Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Morepen Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Morepen Laboratories's annualized EBITDA for the quarter that ended in Dec. 2024 was ₹1,659 Mil. Morepen Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Morepen Laboratories's Debt-to-EBITDA or its related term are showing as below:

NSE:MOREPENLAB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.12   Med: 0.19   Max: 1.3
Current: 0.17

During the past 13 years, the highest Debt-to-EBITDA Ratio of Morepen Laboratories was 1.30. The lowest was 0.12. And the median was 0.19.

NSE:MOREPENLAB's Debt-to-EBITDA is ranked better than
83.38% of 674 companies
in the Drug Manufacturers industry
Industry Median: 1.61 vs NSE:MOREPENLAB: 0.17

Morepen Laboratories Debt-to-EBITDA Historical Data

The historical data trend for Morepen Laboratories's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Morepen Laboratories Debt-to-EBITDA Chart

Morepen Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.13 0.12 0.29 0.17

Morepen Laboratories Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.14 - 0.17 -

Competitive Comparison of Morepen Laboratories's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Morepen Laboratories's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Morepen Laboratories's Debt-to-EBITDA falls into.


;
;

Morepen Laboratories Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Morepen Laboratories's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(256.352 + 33.64) / 1725.954
=0.17

Morepen Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 1659.076
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


Morepen Laboratories  (NSE:MOREPENLAB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Morepen Laboratories Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Morepen Laboratories's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Morepen Laboratories Business Description

Traded in Other Exchanges
Address
Udyog Vihar-III, Sector-20, 2nd Floor, Tower C, DLF Cyber Park, Gurugram, HR, IND, 122016
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.

Morepen Laboratories Headlines

No Headlines